These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25170252)

  • 41. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.
    Bond M; Rabinovich-Guilatt L; Selim S; Darwish M; Tracewell W; Robertson P; Yang R; Malamut R; Colucci P; Ducharme MP; Spiegelstein O
    Clin Drug Investig; 2017 Dec; 37(12):1153-1163. PubMed ID: 28948482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.
    Gammaitoni AR; Davis MW
    J Clin Pharmacol; 2002 Feb; 42(2):192-7. PubMed ID: 11831542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
    Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
    J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist.
    Toyama K; Uchida N; Ishizuka H; Sambe T; Kobayashi S
    J Clin Pharmacol; 2015 Sep; 55(9):975-84. PubMed ID: 25807927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects.
    Im YJ; Jeon JY; Kim EY; Kim Y; Oh DJ; Yoo JS; Shin DH; Chae SW; Kim MG
    Clin Ther; 2015 Feb; 37(2):376-89. PubMed ID: 25618318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
    Weisler RH; Stark JG; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers.
    Encina G; Encabo M; Escriche M; Lahjou M; Sicard E; Smith K; Gascon N; Plata-Salamán C; Videla S
    Clin Drug Investig; 2018 Sep; 38(9):819-827. PubMed ID: 30008052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the effect of naltrexone coadministration on the pharmacokinetics of oxycodone in a randomized phase 1 clinical trial
.
    Kleideiter E; Buller S; Nemeth R; Terlinden R; Rengelshausen J
    Int J Clin Pharmacol Ther; 2020 Aug; 58(8):439-448. PubMed ID: 32507128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study.
    Yue Y; Liu DJ
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):87-94. PubMed ID: 28816033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
    Luo Z; Miao J; Shu S; Wang Y; Zhu X; Hu C; Shen Y
    Clin Drug Investig; 2020 Feb; 40(2):139-148. PubMed ID: 31679120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
    Setnik B; Roland CL; Cleveland JM; Webster L
    Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.